Table 3 Factors associated with the occurrence of 30-day major adverse events
| Â | Univariate analysis | Multivariate analysis | ||
|---|---|---|---|---|
OR (95% CI) | P-value | OR (95% CI) | P-value | |
Age | 0.99 (0.93–1.06) | 0.823 | NA | NA |
Female sex | 0.49 (0.06–3.77) | 0.493 | 0.62 (0.08–4.93) | 0.653 |
BMI | 1.13 (0.95–1.35) | 0.155 | NA | NA |
Smoking | 1.38 (0.44–4.40) | 0.581 | NA | NA |
Diabetes | 1.36 (0.49–3.81) | 0.554 | NA | NA |
Insulin use | 0.77 (0.90–6.53) | 0.809 | NA | NA |
Hypertension | 4.52 (0.59–34.6) | 0.147 | NA | NA |
Dyslipidemia | 0.38 (0.14–1.07) | 0.067 | 0.30 (0.10–0.87) | 0.027 |
CAD | 2.85 (1.00–8.16) | 0.051 | 3.74 (1.25–11.20) | 0.018 |
Subclinical CAD | NA | NA | NA | NA |
CKD | 2.58 (0.87–7.71) | 0.089 | 2.44 (0.80–7.44) | 0.118 |
PAOD | 1.00 (0.13–7.78) | 0.999 | 0.80 (0.10–6.51) | 0.836 |
Degree of stenosis | 0.99 (0.94–1.04) | 0.685 | NA | NA |
SCSO | 2.14 (0.59–7.78) | 0.247 | NA | NA |
Symptomatic stenosis | 0.95 (0.34–2.64) | 0.917 | NA | NA |